Label: MEPROBAMATE- meprobamate tablet

  • NDC Code(s): 55111-640-01, 55111-640-10, 55111-641-01, 55111-641-05
  • Packager: Dr.Reddy's Laboratories Limited
  • This is a repackaged label.
  • Source NDC Code(s): 67787-261 , 67787-262
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: CIV
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated September 9, 2009

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Meprobamate is awhite powder with a characteristic odor and a bittertaste. It is slightly soluble in water, freely soluble in acetone andalcohol, and sparingly soluble in ether. The structural formula of meprobamate is:

    structure 

    C9H18N2O4 M.W.218.25

    Meprobamate Tablets USP 200 mg and 400 mg for oral administrationcontain the following inactive ingredients: microcrystalline cellulose,sodium starch glycolate, pre-gelatinized starch, colloidal silicondioxide, stearic acid and magnesium stearate.

    Close
  • CLINICAL PHARMACOLOGY

    Meprobamate is a carbamate derivative which has been shown inanimal studies to have effects at multiple sites in the central nervoussystem including the thalamus and limbic system.

    Close
  • INDICATIONS AND USAGE

    Meprobamate tablets are indicated for the management of anxietydisorders or for the short-term relief of the symptoms of anxiety.Anxiety or tension associated with the stress of everyday life usuallydo not require treatment with an anxiolytic.

    The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinicalstudies. The physician should periodically reassess the usefulness ofthe drug for the individual patient.

    Close
  • CONTRAINDICATIONS

    Acute intermittent porphyria as well as allergic or idiosyncraticreactions to meprobamate or related compounds such ascarisoprodol, mebutamate, tybamate, or carbromal.

    Close
  • WARNINGS

    Drug Dependence

    Physical dependence, psychological dependence, and abuse haveoccurred. When chronic intoxication from prolonged use occurs, itusually involves ingestion of greater than recommended doses and ismanifested by ataxia, slurred speech, and vertigo. Therefore, carefulsupervision of dose and amounts prescribed is advised, as well asavoidance of prolonged administration, especially for alcoholics andother patients with a known propensity for taking excessive quantitiesof drugs.

    Sudden withdrawal of the drug after prolonged and excessive use mayprecipitate recurrence of pre-existing symptoms such as anxiety,anorexia, insomnia, or withdrawal reactions such as vomiting, ataxia,tremors, muscle twitching, confusional states, hallucinosis, andrarely, convulsive seizures. Such seizures are more likely to occur inpersons with central nervous system damage or pre-existent or latentconvulsive disorders. Onset of withdrawal symptoms occurs usuallywithin 12 to 48 hours after discontinuation of meprobamate;symptoms usually cease within the next 12 to 48 hours.

    When excessive dosage has continued for weeks or months, dosageshould be reduced gradually over a period of one or two weeks ratherthan abruptly stopped. Alternatively, a long-acting barbiturate may besubstituted, then gradually withdrawn.

    Potentially Hazardous Tasks

    Patients should be warned that meprobamate may impair the mentaland/or physical abilities required for performance of potentiallyhazardous tasks such as driving or operating machinery.

    Additive Effects

    Since the effects of meprobamate and alcohol or meprobamate andother CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take morethan one of these agents simultaneously.

    Usage in Pregnancy and Lactation

    An increased risk of congenital malformations associated with theuse of minor tranquilizers (meprobamate, chlordiazepoxide anddiazepam) during the first trimester of pregnancy has beensuggested in several studies. Because use of these drugs is rarelya matter of urgency, their use during this period should almostalways be avoided. The possibility that a woman of childbearingpotential may be pregnant at the time of institution of therapyshould be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant theyshould communicate with their physician about the desirability ofdiscontinuing the drug.

    Meprobamate passes the placental barrier. It is present both inumbilical cord blood at or near maternal plasma levels and inbreast milk of lactating mothers at concentrations two to four timesthat of maternal plasma. When use of meprobamate iscontemplated in breastfeeding patients, the drug's higherconcentration in breast milk as compared to maternal plasmashould be considered.

    Usage in Children

    Meprobamate tablets should not be administered to children underage six, since there is a lack of documented evidence for safety andeffectiveness in this age group.

    Close
  • PRECAUTIONS

    The lowest effective dose should be administered, particularly toelderly and/or debilitated patients, in order to preclude oversedation.

    The possibility of suicide attempts should be considered and the leastamount of drug feasible should be dispensed at anyone time.

    Meprobamate is metabolized in the liver and excreted by the kidney; toavoid its excess accumulation, caution should be exercised inadministration to patients with compromised liver or kidney function.

    Meprobamate occasionally may precipitate seizures in epilepticpatients.

    Geriatric Use

    Clinical studies of meprobamate tablets did not include sufficientnumbers of subjects aged 65 and over to determine whether theyrespond differently from younger subjects. Other reported clinicalexperience has not identified differences in responses between theelderly and younger patients. In general, dose selection for an elderlypatient should be cautious, usually starting at the low end of thedosing range, reflecting the greater frequency of decreased hepatic,renal, or cardiac function, and of concomitant disease or other drug therapy.

    Close
  • ADVERSE REACTIONS

    Central Nervous System

    Drowsiness, ataxia, dizziness, slurred speech, headache, vertigo,weakness, paresthesias, impairment of visual accommodation,euphoria, overstimulation, paradoxical excitement, fast EEG activity.

    Gastrointestinal

    Nausea, vomiting, diarrhea.

    Cardiovascular

    Palpitation, tachycardia, various forms of arrhythmia, transient ECGchanges, syncope; also hypotensive crisis (including one fatal case).

    Allergic or Idiosyncratic

    Allergic or idiosyncratic reactions are usually seen within the period ofthe first to fourth dose in patients having had no previous contact withthe drug. Milder reactions are characterized by an itchy, urticarial, orerythematous maculopapular rash which may be generalized orconfined to the groin. Other reactions have included leukopenia, acutenonthrombocytopenic purpura, petechiae, ecchymoses, eosinophilia,peripheral edema, adenopathy, fever, fixed drug eruption with crossreaction to carisoprodol, and cross sensitivity betweenmeprobamate/mebutamate and meprobamate/carbromal.

    More severe hypersensitivity reactions, rarely reported, includehyperpyrexia, chills, angioneurotic edema, bronchospasm, oliguriaand anuria. Also, anaphylaxis, erythema multiforme, exfoliativedermatitis, stomatitis, proctitis, Stevens-Johnson syndrome andbullous dermatitis, including one fatal case of the latter followingadministration of meprobamate in combination with prednisolone.

    In case of allergic or idiosyncratic reactions to meprobamate,discontinue the drug and initiate appropriate symptomatic therapy,which may include epinephrine, antihistamines, and in severe cases,corticosteroids. In evaluating possible allergic reactions, also considerallergy to excipients.

    Hematologic

    (See also Allergic or Idiosyncratic). Agranulocytosis and aplasticanemia have been reported. These cases rarely were fatal. Rare casesof thrombocytopenic purpura have been reported.

    Other

    Exacerbation of porphyric symptoms.

    Close
  • OVERDOSAGE

    Suicidal attempts with meprobamate have resulted in drowsiness,lethargy, stupor, ataxia, coma, shock, vasomotor, and respiratorycollapse. Some suicidal attempts have been fatal.

    The following data on meprobamate tablets have been reported in theliterature and from other sources. These data are not expected tocorrelate with each case (considering factors such as individual susceptibility and length of time from ingestion to treatment), butrepresent the usual ranges reported.

    Acute simple overdose

    (meprobamate alone): Death has beenreported with ingestion of as little as 12 g meprobamate and survivalwith as much as 40 g.

    Blood levels

    0.5-2 mg% represents the usual blood level range of meprobamateafter therapeutic doses. The level may occasionally be as high as 3mg%.

    3-10 mg% usually corresponds to findings of mild to moderatesymptoms of overdosage, such as stupor or light coma.

    10-20 mg% usually corresponds to deeper coma, requiring moreintensive treatment. Some fatalities occur.

    At levels greater than 20 mg%, more fatalities than survivals can beexpected.

    Acute combined overdose

    (meprobamate with alcohol or other CNSdepressants or psychotropic drugs): Since effects can be additive, ahistory of ingestion of a low dose of meprobamate plus any of thesecompounds (or of a relative low blood or tissue level) cannot be usedas a prognostic indicator.

    In cases where excessive doses have been taken, sleep ensues rapidlyand blood pressure, pulse, and respiratory rates are reduced to basallevels. Any drug remaining in the stomach should be removed andsymptomatic therapy given. Should respiration or blood pressurebecome compromised, respiratory assistance, central nervous systemstimulants, and pressor agents should be administered cautiously asindicated. Meprobamate is metabolized in the liver and excreted by thekidney. Diuresis, osmotic (mannitol) diuresis, peritoneal dialysis, andhemodialysis have been used successfully. Careful monitoring ofurinary output is necessary and caution should be taken to avoidoverhydration. Relapse and death, after initial recovery, have beenattributed to incomplete gastric emptying and delayed absorption.Meprobamate can be measured in biological fluids by two methods:colorimetric (Hoffman, A.J. and Ludwig, B.J.: J Amer Pharm Assn 48:740, 1959) and gas chromatographic (Douglas, J.F. et al: Anal Chern39: 956, 1967).

    Close
  • DOSAGE AND ADMINISTRATION

    Meprobamate Tablets USP: The usual adult daily dosage is 1200 mgto 1600 mg, in three or four divided doses; adaily dosage above 2400mg is not recommended. The usual daily dosage for children ages sixto twelve years is 200 mg to 600 mg, in two or three divided doses.

    Not recommended for children under age 6 (see Usage in Children).

    Close
  • HOW SUPPLIED

    Meprobamate Tablets USP 200 mg are white, round, biconvex tabletsdebossed with I and 7 on one side and bisect on the other.

    Supplied in bottles of 100 and 1000.

    Bottles of 100: NDC 55111-640-01

    Bottles of 1000: NDC 55111-640-10

    Meprobamate Tablets USP 400 mg are white, round, biconvex tabletsdebossed with I and 4 on one side and bisect on the other.

    Supplied in bottles of 100 and 500.

    Bottles of 100: NDC 55111-641-01

    Bottles of 500: NDC 55111-641-05

    Dispense in well-closed container with child-resistant closure.

    Store at 20°-25°C (68°-77°F) [see USP Controlled RoomTemperature].

    Manufactu red by:

    InvaGen Pharmaceuticals, Inc

    Hauppauge, NY 11788

    Manufactured for:

    Dr. Reddy's Laboratories Inc.,

    Bridgewater, NJ 08807 USA

    Rev: 05/09

    Close
  • SPL UNCLASSIFIED SECTION

    200 mg - CONTAINER LABELS

    100's count

    200-100

    1000's count

    200-1000

    400 mg - CONTAINER LABELS

    100's count

    400-100

    500's count

    400-500

    Close
  • INGREDIENTS AND APPEARANCE
    MEPROBAMATE 
    meprobamate tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55111-640(NDC:67787-261)
    Route of Administration ORAL DEA Schedule CIV    
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Meprobamate (UNII: 9I7LNY769Q) (meprobamate - UNII:9I7LNY769Q) Meprobamate 200 mg
    Inactive Ingredients
    Ingredient Name Strength
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    colloidal silicon dioxide (UNII: ETJ7Z6XBU4)  
    stearic acid (UNII: 4ELV7Z65AP)  
    magnesium stearate (UNII: 70097M6I30)  
    sodium starch glycolate type A potato (UNII: 5856J3G2A2)  
    Product Characteristics
    Color WHITE Score 2 pieces
    Shape ROUND Size 9mm
    Flavor Imprint Code I;7
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55111-640-01 100 in 1 BOTTLE
    2 NDC:55111-640-10 1000 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040797 01/03/2008
    MEPROBAMATE 
    meprobamate tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55111-641(NDC:67787-262)
    Route of Administration ORAL DEA Schedule CIV    
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Meprobamate (UNII: 9I7LNY769Q) (meprobamate - UNII:9I7LNY769Q) Meprobamate 400 mg
    Inactive Ingredients
    Ingredient Name Strength
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    colloidal silicon dioxide (UNII: ETJ7Z6XBU4)  
    stearic acid (UNII: 4ELV7Z65AP)  
    magnesium stearate (UNII: 70097M6I30)  
    Product Characteristics
    Color WHITE Score 2 pieces
    Shape ROUND Size 11mm
    Flavor Imprint Code I;4
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55111-641-01 100 in 1 BOTTLE
    2 NDC:55111-641-05 500 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040797 01/03/2008
    Labeler - Dr.Reddy's Laboratories Limited (862179079)
    Establishment
    Name Address ID/FEI Business Operations
    InvaGen Pharmaceuticals, Inc. 165104469 analysis, manufacture
    Close